SMRX 11

Drug Profile

SMRX 11

Alternative Names: Clot-buster protein; Clot-specific streptokinase; CSSK; SMRX11

Latest Information Update: 01 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute of Microbial Technology
  • Developer Nostrum Pharmaceuticals; Symmetrix Biotech
  • Class Coenzymes; Plasminogen activator enzymes; Recombinant fusion proteins; Recombinant proteins; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myocardial infarction
  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in India (IV)
  • 24 Mar 2014 SMRX 11 is still in preclinical trials for thrombosis (IV) in India
  • 10 Mar 2014 Symmetrix Pharmaceuticals plans a phase II trial for Myocardial infarction in India (CTRI/2014/03/004442)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top